| 0 (0%) | 11-30 07:30 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.01 |
1-year : | 1.13 |
| Resists | First : | 0.87 |
Second : | 0.96 |
| Pivot price | 0.77  |
|||
| Supports | First : | 0.7 |
Second : | 0.59 |
| MAs | MA(5) : | 0.78 |
MA(20) : | 0.77 |
| MA(100) : | 0.65 |
MA(250) : | 0.78 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 48.8 |
D(3) : | 43.3 |
| RSI | RSI(14): 49.2 |
|||
| 52-week | High : | 2.22 | Low : | 0.16 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ATXI ] has closed above bottom band by 38.4%. Bollinger Bands are 51.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.87 - 0.87 | 0.87 - 0.88 |
| Low: | 0.76 - 0.76 | 0.76 - 0.76 |
| Close: | 0.86 - 0.87 | 0.87 - 0.88 |
Fri, 14 Nov 2025
Avenue Therapeutics Reports Improved Financials Amid Challenges - The Globe and Mail
Thu, 13 Nov 2025
Avenue Therapeutics Sells Baergic Bio to Axsome - The Globe and Mail
Tue, 11 Nov 2025
Avenue Therapeutics announces Baergic Bio acquisition by Axsome - MSN
Thu, 06 Nov 2025
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics - GlobeNewswire
Thu, 06 Nov 2025
Avenue Therapeutics (ATXI) Sells Baergic Bio to Axsome Therapeutics - GuruFocus
Thu, 06 Nov 2025
Avenue (OTC: ATXI): Axsome to acquire Baergic; up to $82M milestones, royalties - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 3 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 18.4 (%) |
| Held by Institutions | 3.1 (%) |
| Shares Short | 60 (K) |
| Shares Short P.Month | 155 (K) |
| EPS | 2.57 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.33 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0.29 |
| PEG Ratio | 0 |
| Price to Book value | 0.57 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|